Ticker
AKBA

Price
1.07
Stock movement up
+0.01 (0.94%)
Company name
Akebia Ther
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
197.15M
Ent value
449.17M
Price/Sales
0.67
Price/Book
21.10
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
295.56%
3 year return
-31.37%
5 year return
-33.36%
10 year return
-
Last updated: 2023-12-01
Akebia Therapeutics, Inc. (NASDAQ:NASDAQ:AKBA) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ETCompany ParticipantsMercedes Carrasco - Senior...
November 8, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
November 8, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

AKBA does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales0.67
Price to Book21.10
EV to Sales1.54
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
November 7, 2023

iO Charts is a Seeking Alpha partner

Akebia Therapeutics is awaiting an FDA decision on Vafseo expected in March 2024, supported by positive post-marketing safety data. Learn more on AKBA stock here.
November 3, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count184.25M
EPS (TTM)-0.50
FCF per share (TTM)-0.40

Income statement

Loading...
Income statement data
Revenue (TTM)292.60M
Gross profit (TTM)201.62M
Operating income (TTM)-85.30M
Net income (TTM)-92.56M
EPS (TTM)-0.50
EPS (1y forward)-0.25

Margins

Loading...
Margins data
Gross margin (TTM)68.90%
Operating margin (TTM)-29.15%
Profit margin (TTM)-31.63%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash90.47M
Net receivables39.18M
Total current assets90.47M
Goodwill55.05M
Intangible assets72.08M
Property, plant and equipment0.00
Total assets351.83M
Accounts payable18.02M
Short/Current long term debt95.04M
Total current liabilities124.76M
Total liabilities342.49M
Shareholder's equity9.34M
Net tangible assets-117.80M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-73.15M
Capital expenditures (TTM)114.00K
Free cash flow (TTM)-73.15M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-990.82%
Return on Assets-26.31%
Return on Invested Capital-223.89%
Cash Return on Invested Capital-176.95%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.06
Daily high1.09
Daily low1.02
Daily Volume1.19M
All-time high29.17
1y analyst estimate1.63
Beta0.83
EPS (TTM)-0.50
Dividend per share-
Ex-div date-
Next earnings date7 Mar 2024

Downside potential

Loading...
Downside potential data
AKBAS&P500
Current price drop from All-time high-96.33%-3.90%
Highest price drop-99.14%-56.47%
Date of highest drop29 Nov 20229 Mar 2009
Avg drop from high-73.05%-11.47%
Avg time to new high407 days13 days
Max time to new high2380 days1805 days
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
October 25, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
September 28, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
AKBA (Akebia Ther) company logo
Marketcap
197.15M
Marketcap category
Small-cap
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Employees
204
Investor relations
-
SEC filings
CEO
John P. Butler
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
September 26, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 28, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 25, 2023
Akebia Therapeutics, Inc. (NASDAQ:NASDAQ:AKBA) Q2 2023 Earnings Conference Call August 25, 2023 9:00 AM ETCompany ParticipantsMercedes Carrasco - Senior...
August 25, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 24, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 24, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
August 10, 2023
Akebia Therapeutics plans to resubmit kidney disease drug application, while its stock outperforms S&P 500 and shows promising growth potential. Read why AKBA is a Hold.
August 2, 2023
Akebia Therapeutics is cash poor, has large debt, and its Q2 revenues are unlikely to meet analyst estimates. Read about AKBA's upcoming post-earnings catalysts.
August 2, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
July 18, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
June 20, 2023
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
June 13, 2023
iO Charts is a Seeking Alpha partnerNext page